Primary Sclerosing Cholangitis Market Outlook Highlights Rising Demand and Expanding Treatment Landscape Throughout the Forecast Period (2025-2034) | DelveInsight
According to DelveInsight's analysis, the primary sclerosing cholangitis market is anticipated to grow during the forecast period (2025–2034), driven by the launch of emerging therapies such as LB-P8 (LISCure Biosciences), Volixibat (Mirum Pharmaceuticals), IQIRVO (Elafibranor) (Ipsen), Nebokitug (Chemomab Therapeutics), and others, and healthcare spending in the 7MM.
LAS VEGAS, Feb. 5, 2026 /PRNewswire/ -- DelveInsight's Primary Sclerosing Cholangitis Market Insights report includes a comprehensive understanding of current treatment practices, primary sclerosing cholangitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Primary Sclerosing Cholangitis Market Summary
Discover how large is the PSC market now and what will it be in 2034 @ https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the Growth of the Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis Market Analysis
Primary Sclerosing Cholangitis Competitive Landscape
Some of the PSC therapies in the pipeline include LB-P8 (LISCure Biosciences), Volixibat (Mirum Pharmaceuticals), IQIRVO (Elafibranor) (Ipsen), Nebokitug (Chemomab Therapeutics), and others.
LISCure Biosciences' LB-P8 is an orally administered, once-daily live biotherapeutic consisting of a single microbial strain designed to modulate fibrosis and inflammation via the gut–liver axis. Its anti-fibrotic and anti-inflammatory activity has been demonstrated across multiple preclinical models, including primary sclerosing cholangitis (PSC), metabolic dysfunction–associated steatohepatitis (MASH), and inflammatory bowel disease (IBD).
Mirum Pharmaceuticals' Volixibat is an oral, minimally absorbed inhibitor of the ileal bile acid transporter (IBAT) that reduces bile acid levels by preventing their intestinal reabsorption, thereby lowering systemic and hepatic bile acid exposure. The compound is currently being evaluated in the Phase IIb VISTAS trial for PSC. In 2024, the study met its prespecified efficacy and safety criteria at a blinded interim analysis for dose selection, highlighting its encouraging clinical potential. No new safety signals were observed, with diarrhea as the most common mild-to-moderate adverse event.
Ipsen's Elafibranor is an oral agonist of peroxisome proliferator-activated receptors (PPAR) α and δ. Activation of these receptors reduces bile acid toxicity and improves cholestasis by regulating bile acid synthesis, detoxification, and transporter expression. In addition, activation of PPARα and PPARδ confers anti-inflammatory effects through multiple signaling pathways.
The anticipated launch of these emerging therapies are poised to transform the primary sclerosing cholangitis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the primary sclerosing cholangitis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about which emerging drugs will affect the PSC market @ Primary Sclerosing Cholangitis Drugs Market
Recent Developments in the Primary Sclerosing Cholangitis Market
What is Primary Sclerosing Cholangitis?
Primary sclerosing cholangitis (PSC) is a rare, chronic liver disease characterized by ongoing inflammation, fibrosis, and progressive narrowing of the bile ducts inside and outside the liver. This leads to impaired bile flow (cholestasis), causing bile to accumulate in the liver and gradually resulting in liver damage, cirrhosis, and eventually liver failure in some patients. PSC is strongly associated with inflammatory bowel disease, particularly ulcerative colitis, and often affects younger to middle-aged adults. The disease course is variable and unpredictable, with patients at increased risk of complications such as recurrent cholangitis, cholangiocarcinoma, and colorectal cancer. Currently, there is no curative medical therapy for PSC, and liver transplantation remains the only definitive treatment for advanced disease.
Primary Sclerosing Cholangitis Epidemiology Segmentation
The primary sclerosing cholangitis epidemiology section provides insights into the historical and current primary sclerosing cholangitis patient pool and forecasted trends for the leading markets. PSC affects men about twice as often as women. Although it can occur at any age, it most commonly develops in middle-aged adults.
The primary sclerosing cholangitis treatment market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:
Primary Sclerosing Cholangitis Market Forecast Report Metrics
Details
Study Period
2020–2034
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Primary Sclerosing Cholangitis Epidemiology Segmentation
Total Prevalent Cases of PSC, Total Diagnosed Prevalent Cases of PSC, Gender-specific Cases of PSC, Comorbidity-specific Cases of PSC, and Treated Cases of PSC
Key Primary Sclerosing Cholangitis Companies
LISCure Biosciences, Mirum Pharmaceuticals, Ipsen, Chemomab Therapeutics, and others
Key Primary Sclerosing Cholangitis Therapies
LB-P8, Volixibat, IQIRVO (Elafibranor), Nebokitug, and others
Scope of the Primary Sclerosing Cholangitis Market Report
Download the report to understand what factors are driving the PSC therapeutic market @ Primary Sclerosing Cholangitis Market Forecast
Table of Contents
1
Primary Sclerosing Cholangitis Market Key Insights
2
Primary Sclerosing Cholangitis Market Report Introduction
3
PSC Market Overview at a Glance
3.1
Market Share (%) Distribution of PSC by Therapies in 2020
3.2
Market Share (%) Distribution of PSC by Therapies in 2034
4
Epidemiology and Market Forecast Methodology
5
Executive Summary
6
Key Events
7
Disease Background and Overview
7.1
Introduction
7.2
Clinical Manifestations
7.3
Causes and Risk Factors
7.4
Pathophysiology
7.5
Diagnosis
7.6
Primary Sclerosing Cholangitis Treatment and Management
8
Epidemiology and Patient Population
8.1
Key Findings
8.2
Assumptions and Rationale: 7MM
8.3
Total Diagnosed Prevalent Cases of PSC in the 7MM
8.4
The United States
8.4.1
Total Prevalent Cases of PSC
8.4.2
Total Diagnosed Prevalent Cases of PSC
8.4.3
Gender-specific Cases of PSC
8.4.4
Comorbidity-specific Cases of PSC
8.4.5
Treated Cases of PSC
8.5
EU4 and the UK
8.6
Japan
9
Primary Sclerosing Cholangitis Patient Journey
10
Emerging Primary Sclerosing Cholangitis Drugs
10.1
Key Cross Competition
10.2
LB-P8: LISCure Biosciences
10.2.1
Product Description
10.2.2
Other Development Activities
10.2.3
Clinical Trial Information
10.2.4
Safety and Efficacy
10.2.5
Analyst Views
10.3
Volixibat: Mirum Pharmaceuticals
10.4
IQIRVO (Elafibranor): Ipsen
To be Continued in Report….
11
PSC Market: Major Market Analysis
11.1
Key Findings
11.2
Key Primary Sclerosing Cholangitis Market Forecast Assumptions
11.3
Primary Sclerosing Cholangitis Market Outlook
11.4
Attribute Analysis
11.5
Total Market Size of PSC in the 7MM
11.6
Total Market Size of PSC by Therapies in the 7MM
11.7
The United States Primary Sclerosing Cholangitis Market Size
11.7.1
Total Market Size of PSC in the US
11.7.2
Market Size of PSC by Therapies in the US
11.8
EU4 and the UK Primary Sclerosing Cholangitis Market Size
11.9
Japan Primary Sclerosing Cholangitis Market Size
12
KOL Opinion Leaders' Views on PSC
13
Primary Sclerosing Cholangitis Market SWOT Analysis
14
Primary Sclerosing Cholangitis Market Unmet Needs
15
Primary Sclerosing Cholangitis Market Access and Reimbursement
16
Acronym and Abbreviations
17
Bibliography
18
Primary Sclerosing Cholangitis Market Report Methodology
Related Reports
Primary Sclerosing Cholangitis Clinical Trial Analysis
Primary Sclerosing Cholangitis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Primary Sclerosing Cholangitis companies, including Gilead Sciences, Immunic, Dr Falk Pharma, Pliant Therapeutics, CymaBay Therapeutics, SCOHIA PHARMA, Albireo Pharma, Sirnaomics, Morphic Therapeutic, and others.
Inflammatory Bowel Disease Market
Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key IBD companies including Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead Sciences, Arena Pharmaceuticals, Eli Lilly, AstraZeneca, and others.
Ulcerative Colitis Market
Ulcerative Colitis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ulcerative colitis companies including Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck, Mesoblast, and others.
Crohn's Disease Market
Crohn's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Crohn's disease companies including RedHill Biopharma, Merck, Teva Pharmaceutical, Pfizer, Agomab Therapeutics, Sanofi, Medibiofarma, Eli Lilly, NImmune, Avobis Bio, Abivax, Roche, Telavant, Mesoblast, Takeda, AstraZeneca, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP